Table 3 Registered clinical trials targeting RNA sensors for cancers (https://clinicaltrials.gov/)
From: Emerging role of RNA sensors in tumor microenvironment and immunotherapy
Target | Drug name | Cancer | Combination agent | Phase | Start date/last update | Status | NCT number |
|---|---|---|---|---|---|---|---|
TLR3 MDA5 | Poly-ICLC (Hiltonol®) | Melanoma | NY-ESO-1, Montanide | I/II | March 2010/February 2018 | Completed | NCT01079741 |
| Â | Â | Melanoma | NA | I | February 2013/October 2015 | Terminated | NCT01783431 |
| Â | Â | B cell and T cell lymphoma | NA | I | April 2009/July 2011 | Terminated | NCT00880867 |
| Â | Â | Low-grade B-cell lymphoma | rhuFlt3L/CDX-301 | I/II | November 2013/November 2020 | Recruiting | NCT01976585 |
| Â | Â | Non-Hodgkin's lymphoma, Metastatic breast cancer HNSCC | Pembrolizumab, Flt3L, Radiation | I/II | December 2018/October 2021 | Recruiting | NCT03789097 |
| Â | Â | Solid tumor | Durvalumab Tremelimumab | I/II | December 2015/March 2022 | Completed | NCT02643303 |
| Â | Â | Solid tumor | NA | II | April 2015/December 2020 | Completed | NCT02423863 |
| Â | Â | Solid tumor | NA | II | November 2013/January 2018 | Terminated | NCT01984892 |
| Â | Â | Solid tumor | aPD-1 or aPD-L1 | I/II | October 2018/February 2021 | Terminated | NCT03721679 |
| Â | Â | Brain tumors | NA | II | August 2010/September 2021 | Completed | NCT01188096 |
| Â | Â | Brain tumors | Peptide vaccine | I | April 2009/December 2015 | Completed | NCT00874861 |
| Â | Â | Brain tumors | IMA950, Varlilumab | I | October 2016/July 2021 | Active, not recruiting | NCT02924038 |
| Â | Â | CNS tumor | IMA 950 | I/II | August 2013/April 2016 | Completed | NCT01920191 |
| Â | Â | Primary ovarian cancer Fallopian tube cancer Primary peritoneal cancer | OC-L, Montanide | I | May 2015/April 2020 | Terminated | NCT02452775 |
| Â | Â | Ovarian cancer | Oregovomab | I | May 2017/December 2020 | Terminated | NCT03162562 |
| Â | Â | Prostate cancer | NA | I | August 2017/April 2021 | Recruiting | NCT03262103 |
| Â | Â | Glioma Glioblastoma | DC vaccination Resiquimod | II | September 2010/February 2022 | Active, not recruiting | NCT01204684 |
| Â | Â | Glioblastoma | IMA950, Pembrolizumab | I/II | September 2018/December 2020 | Recruiting | NCT03665545 |
| Â | Â | Low-grade glioma | NA | II | September 2020/February 2022 | Recruiting | NCT04544007 |
| Â | Â | Solid tumor | Pembrolizumab | I/II | July 2016/July 2021 | Recruiting | NCT02834052 |
TLR3 MDA5 | BO-112 | Melanoma | Pembrolizumab | II | September 2020/February 2022 | Active, not recruiting | NCT04570332 |
TLR3 | Rintatolimod | Recurrent ovarian cancer | Pembrolizumab Cisplatin | I/II | November 2018/March 2022 | Recruiting | NCT03734692 |
| Â | Ampligen (rintatolimod) | Ovarian cancer Fallopian tube cancer Primary peritoneal cancer | OC-L/Montanide ISA 51 VG, Prevnar | I/II | March 2011/November 2021 | Terminated | NCT01312389 |
| Â | Â | Breast cancer | Celecoxib, Cyclophosphamide, Doxorubicin, Paclitaxel | I | September 2019/September 2021 | Recruiting | NCT04081389 |
TLR7 | Imiquimod | Cervical squamous cell carcinoma | Topical Fluorouracil | I | June 2017/February 2022 | Active, not recruiting | NCT03196180 |
| Â | Â | Breast cancer | NA | II | May 2009/December 2015 | Completed | NCT00899574 |
| Â | Â | Breast cancer | Radiation Cyclophosphamide | I/II | August 2011/November 2021 | Completed | NCT01421017 |
| Â | Â | Solid tumor | Echopulse PD-1 | I | October 2019/August 2021 | Recruiting | NCT04116320 |
| Â | RO7119929 | Liver cancer | Tocilizumab | I | April 2020/March 2022 | Recruiting | NCT04338685 |
| Â | SHR2150 | Solid tumor | Anti-Cancer Agent | I/II | October 2020/October 2020 | Recruiting | NCT04588324 |
| Â | 852A | Breast cancer Ovarian cancer Endometrial cancer Cervical cancer | NA | II | April 2006/August 2019 | Completed | NCT00319748 |
| Â | LHC165 | Solid tumor | PDR001 | I | October 2017/December 2021 | Active, not recruiting | NCT03301896 |
| Â | BNT411 | Solid tumor | Atezolizumab Carboplatin Etoposide | I/II | September 2019/July 2021 | Recruiting | NCT04101357 |
| Â | TQ-A3334 | NSCLC | Anlotinib | I/II | February 2020/July 2020 | Recruiting | NCT04273815 |
TLR7/8 | Resiquimod | Solid tumor | Pembrolizumab | I/II | March 2021/March 2022 | Recruiting | NCT04799054 |
| Â | Â | Tumors | NY-ESO-1 | I | January 2009/January 2015 | Completed | NCT00821652 |
| Â | MEDI9197 | Solid tumor | Durvalumab | I | September 2015/December 2018 | Terminated | NCT02556463 |
| Â | NKTR-262 | Solid tumor | Bempegaldesleukin Nivolumab | I/II | February 2018/March 2022 | Active, not recruiting | NCT03435640 |
| Â | BDB018 | Solid tumor | Pembrolizumab | I | April 2021/August 2021 | Recruiting | NCT04840394 |
| Â | NKTR-262 | Solid tumor | Bempegaldesleukin Nivolumab | I/II | February 2018/March 2022 | Active, not recruiting | NCT03435640 |
| Â | BDC-1001 | HER2 positive solid tumors | Nivolumab | I/II | February 2020/January 2022 | Recruiting | NCT04278144 |
TLR8 | VTX-2337 (Motolimod) | Solid tumor | Cyclophosphamide Pegfilgrastim | I | January 2016/September 2018 | Terminated | NCT02650635 |
| Â | Â | Ovarian cancer | Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel | I | February 2011/December 2014 | Completed | NCT01294293 |
| Â | Â | Low-grade B cell lymphoma | Radiotherapy | I/II | February 2011/September 2019 | Terminated | NCT01289210 |
| Â | Â | SCCHN | Carboplatin Cisplatin 5-fluorouracil | II | April 2013/October 2019 | Completed | NCT01836029 |
| Â | Â | SCC | Nivolumab | I | April 2019/February 2022 | Completed | NCT03906526 |
| Â | Â | Ovarian cancer | Durvalumab, PLD | I/II | May 2015/September 2021 | Completed | NCT02431559 |
| Â | Â | Epithelial ovarian cancer Fallopian yube cancer Primary peritoneal cancer | PLD | II | August 2012/September 2019 | Completed | NCT01666444 |
| Â | SBT6050 | HER2 positive solid tumors | Trastuzumab Deruxtecan, Tucatinib, Trastuzumab, Capecitabine | I/II | October 2021/March 2022 | Recruiting | NCT05091528 |
| Â | Â | HER2 positive solid tumors | Pembrolizumab Cemiplimab | I | July 2020/March 2022 | Recruiting | NCT04460456 |
TLR7/8, RIG-I | CV8102 | Solid tumors | Anti-PD-1 therapy | I | September 2017/November 2021 | Active, not recruiting | NCT03291002 |
RIG-I | MK-4621 | Advanced solid tumors | Pembrolizumab | I | November 2018/February 2022 | Terminated | NCT03739138 |